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Purpose
Dose-dense chemotherapy (DD-CT) is a preferred (neo)adjuvant regimen in early breast can-
cer (BC). Although the results of reported randomized trials are conflicting, a recent meta-
analysis showed improved overall and disease-free survival with DD-CT compared to con-
ventional schedules. However, no DD-CT safety data for Korean BC patients are available.
This phase II study was conducted to evaluate the safety and efficacy of pegteograstim in
Korean BC patients receiving DD-CT.    
Materials and Methods
Patients with operable (stage I-III), histologically confirmed BC received four cycles of intra-
venous doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) on day 1 every 
2 weeks as neoadjuvant or adjuvant therapy. Pegteograstim (6.0 mg) was administered
subcutaneously on day 2 of each cycle. The primary endpoint was the incidence of febrile
neutropenia (FN). The secondary endpoints were safety and tolerability.
Results
Of 63 patients, one (1.6%) developed FN during all cycles of DD-CT. Dose delay was 
observed in four patients (6.3%) and dose reduction in two (3.2%) during DD-CT. Frequent
adverse events (AEs) were nausea, alopecia, generalized muscle weakness, myalgia, 
mucositis, anorexia, dyspepsia, and diarrhea; most AEs were related to chemotherapy.
Grade 3-4 AEs were reported in five of 63 patients (7.9%), and all grade 3 and 4 AEs were
related to chemotherapy. Adverse drug reactions possibly linked to pegteograstim were 
abdominal pain, bone pain, myalgia, generalized muscle weakness, and headache in five
of 63 patients (7.9%).
Conclusion
Dose-dense AC (doxorubicin/cyclophosphamide) chemotherapy with pegteograstim support
is a tolerable and safe regimen in Korean early BC patients.
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Introduction
Anthracycline followed by taxane chemotherapy regimens
are considered the standard of care as neoadjuvant or adju-
vant chemotherapy for early breast cancer [1]. The introduc-
tion of granulocyte colony stimulating factor (G-CSF) ena-
bled dose-dense chemotherapy (DD-CT), defined as the 
administration of the standard dose chemotherapy over
shorter intervals per cycle. The National Comprehensive
Cancer Network guidelines recommend a DD regimen as the
preferred treatment based on the results of several random-
ized trials that showed the superiority of DD-CT [2-4]. A 
recent meta-analysis also reported that DD-CT with G-CSF
support lowers the risk of recurrence and breast cancer death
by approximately 15% in cases of early breast cancer [5].
However, along with the increase in efficacy, DD-CT has
the potential to increase toxicity. Several prospective DD-CT
trials reported that DD-CT was associated with an increased
rate of non-hematologic and hematologic toxicities [2,3,6-9].
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Waks et al. [10] reported that the DD-CT regimen was a risk
factor for Pneumocystis jirovecii pneumonia (PJP) in a retro-
spective review of a large population (n=3,322). In addition,
limited safety data of DD-CT in Asian breast cancer patients
are available, and several studies have shown that the inci-
dence of chemotherapy-related toxicities differs between eth-
nic groups [11-15]. An investigation of the safety profiles of
DD-CT with long-acting G-CSF in Asian breast cancer pati-
ents is needed.
Pegteograstim, a novel long-acting recombinant human 
G-CSF, has higher biological activity based on its higher
affinity to the G-CSF receptor than pegfilgrastim [16-18].
Here, we evaluated the safety and efficacy of pegteograstim
in Korean early breast cancer patients receiving DD-AC (dox-
orubicin/cyclophosphamide) regimen. 
Materials and Methods
1. Study design and patients
This was a single arm, phase II trial conducted at Yonsei
Cancer Center in Korea. 
Eligible patients were women with histologically con-
firmed, operable primary breast cancer without distant
metastases. The planned regimen was AC (doxorubicin 60
mg/m2 and cyclophosphamide 600 mg/m2) chemotherapy
as neoadjuvant or adjuvant therapy for breast cancer. Pati-
ents had to have an Eastern Cooperative Oncology Group
(ECOG) Performance Status score of 0 or 1 and no major car-
diovascular morbidity or other serious medical conditions.
The main exclusion criteria were previous adjuvant or neo-
adjuvant treatment, ongoing pregnancy or lactation, abnor-
mal laboratory values precluding the possibility to safely
deliver the cytotoxic agents used in the study, and previous
or concurrent malignant neoplasms at the other sites.
2. Procedures
Patients received four cycles of DD-AC (60 mg/m2 dox-
orubicin and 600 mg/m2 cyclophosphamide administered
intravenously on day 1 every 2 weeks). A fixed dose of 6.0
mg pegteograstim was administered subcutaneously on day
2 of each chemotherapy cycle (between 22 and 26 hours after
the completion of chemotherapy). Patients with lymph node
metastases were treated with taxane chemotherapy (weekly
paclitaxel or docetaxel every 3 weeks). Taxane regimen was
decided by investigator’s discretion.
Blood sampling for hematological and biochemical assess-
ments was done on day 1 of each cycle and 4 weeks after the
last chemotherapy (end of treatment visit). Chemotherapy
was administered only if absolute neutrophil count was 
 1.0103 cells/L and platelet counts were  100103/L. Sup-
portive care was provided as per the local policy. A dose
delay of up to 14 days was allowed to achieve these hemato-
logic parameters. Adverse events (AEs) were graded using
the National Cancer Institute Common Terminology Criteria
for Adverse Events (NCI-CTCAE ver. 4.03).
3. Outcomes
The primary endpoint was the incidence of febrile neu-
tropenia (FN) in DD-AC with pegteograstim. FN was defi-
ned as neutropenia (< 500 neutrophils/µL) with a febrile
event (a single oral temperature of  38.3°C or a temperature
of  38.0°C sustained over a 1-hour period). Secondary end-
points were the incidences of FN in the first cycle of DD-AC,
hospitalization for FN, grade 3 or 4 neutropenia in the first
cycle of DD-AC, and the dose delay or reduction of chemo-
therapy. Safety was also a secondary endpoint and was 
assessed throughout the study treatment according to the
NCI-CTCAE ver. 4.03.
4. Statistical considerations
In previous DD-CT trials, the incidence of FN in DD-AC
ranged widely from 1% to 10% and several guidelines cate-
gorize the AC regimen into the intermediate risk group (risk
of FN ranges from 10%-25%). Based on those results, we 
hypothesized that threshold and expected values of the inci-
dences of FN were 5% and 20%, respectively. To meet the
threshold and expected values of the incidence of FN with a
type I error level of 0.05 and type II error level of 0.20, at least
56 patients were required. As a dropout rate of 10% is 
expected, we aimed to recruit 63 patients. Statistical analyses
were performed using SPSS ver. 22.0 for Window (IBM
Corp., Armonk, NY). Descriptive statistics were used for
baseline characteristics. Binomial two-sided 95% confidence
intervals (CIs) for the change of hematology profile were cal-
culated. 
5. Ethical statement
All patients provided written informed consent before 
enrollment. The study protocol was approved by the institu-
tional review board (IRB No. 4-2015-0813). The study was
conducted according to the Declaration of Helsinki and the
principles of good clinical practice. The trial was registered
at ClinicalTrials.gov (NCT03575520).
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Results
1. Patient characteristics
Between June 2016 and March 2017, a total of 63 patients
were enrolled at Yonsei Cancer Center. The characteristics of
the patients included in this study are shown in Table 1. The
median (range) age was 50 years (range, 29 to 69 years), and
all patients had an ECOG performance status score of 0. Of
the 63 patients, 42 (66.7%) were premenopausal women, and
37 (58.7%) were node positive, 22 (24.9%) had grade 3 dis-
ease, 18 (28.6%) received neoadjuvant therapy, 37 (58.7%)
had estrogen receptor– or progesterone receptor–positive 
tumors, and 20 (31.7%) had human epidermal growth factor
receptor 2–positive tumors. 
2. The incidence of FN and dose intensity
Only one of 63 patients (1.6%) developed FN during DD-AC
chemotherapy. All patients, except one who withdrew from
the study after the first cycle of chemotherapy, completed the
planned four cycles of DD-AC chemotherapy. Dose delay
was observed in four of 63 patients (6.3%) during DD-AC.
The duration of dose delay was seven days for all four 
patients. The reasons for the dose delay were AEs in two 
patients (liver enzyme elevation grade 3 and mucositis grade
2). The other two patients visited 1 week later due to a mis-
taken appointment without any reason for the dose delay.
Dose reduction was observed in two of 63 patients (3.2%)
during DD-AC. The reasons for the dose reductions were 
recurrent grade 3 FN and grade 3 mucositis in each patient.
3. Safety
The most frequently reported AEs are presented in Table 2.
All but one of the 63 patients (98.4%) reported at least one
AE during DD-AC chemotherapy with pegteograstim sub-
cutaneous injection. Grade 3 to 4 AEs were reported in five
of 63 patients (7.9%). All grade 3 or 4 AEs were linked to
chemotherapy (grade 3 FN, grade 3 anemia, grade 3 pneu-
monia, grade 3 mucositis, grade 3 wound infection, and
grade 4 neutropenia). One patient withdrew from the study
after the first cycle of chemotherapy due to toxicity (pneu-
monia). She refused further adjuvant chemotherapy. The
most frequent AEs were nausea, alopecia, generalized mus-
cle weakness, myalgia, mucositis, anorexia, dyspepsia, diar-
rhea, and most AEs were due to the chemotherapy. Adverse
drug reactions (ADRs) that might be linked to pegteograstim
included abdominal pain, bone pain, myalgia, generalized
muscle weakness, and headache in five of 63 patients (7.9%).
Ten patients experience infectious AEs. Regarding to the type
of infections, cystitis is most common with six cases (60%)
and the remainder were pneumonia, febrile neutropenia, 
enteritis, esophageal candidiasis, respectively.
4. Change of hematology profile
The change in hematology profiles (neutrophil, lympho-
cyte, platelet counts, and hemoglobin level) at day 1 of each
cycle and follow-up is shown in Fig. 1. Mean absolute lym-
phocyte counts and hemoglobin level decreased gradually
during DD-AC chemotherapy and at the follow-up visit.
Mean platelet counts decreased gradually during DD-AC
Table 1. Baseline characteristics
TNM, tumor node metastasis; HR, hormone receptor;
HER2, human epidermal growth factor receptor 2.
No. (%) (n=63)
Age, median (range, yr) 50 (29-69)
Menopausal status
Premenopausal 42 (66.7)
Postmenopausal 21 (33.3)
Type of surgery
Mastectomy 23 (36.5)
Breast-conserving surgery 40 (63.5)
T category
T1 26 (41.3)
T2 28 (44.4)
T3 9 (14.3)
N category
0 26 (41.3)
1 28 (44.4)
2 4 (6.3)
3 5 (7.9)
Tumor grade
1 3 (4.8)
2 35 (55.6)
3 22 (34.9)
Missing 3 (4.8)
TNM stage
1 29 (46.0)
2 28 (44.4)
3 6 (9.5)
Subtype
HR+/HER2– 32 (50.8)
HR+/HER2+ 5 (7.9)
HR–/HER2+ 15 (23.8)
HR–/HER2– 11 (17.5)
Treatment setting
Neoadjuvant 18 (28.6)
Adjuvant 45 (71.4)
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chemotherapy but recovered to baseline levels at follow-up.
In contrast, mean neutrophil counts were increased during
DD-AC but subsequently returned to baseline level at fol-
low-up.
Discussion
To the best of our knowledge, this study is the first to eval-
uate the efficacy and safety of long acting G-CSF, pegteogras-
tim during DD-AC chemotherapy in Korean early breast
cancer patients. We found that FN occurred in only 1.6% of
patients receiving DD-AC chemotherapy with pegteograstim
support. Grade 3 to 4 AEs were reported in five of 63 patients
(7.9%). All but one patient completed the planned four cycles
of DD-AC chemotherapy. Dose delay and dose reduction
linked to AEs were observed in two of 63 patients (3.2%). The
most common ADRs possibly linked to pegteograstim were
abdominal pain, bone pain, myalgia, generalized muscle
weakness, and headache.
CALGB 9741 trial was the first large phase III study to
demonstrate that DD-CT improved clinical outcomes regard-
ing both disease-free survival (DFS) and overall survival (OS)
in node-positive breast cancer [3]. Similarly, the GIM-II trial
showed that DD-CT improved DFS and OS compared to a
conventional chemotherapy schedule. In contrast, several tri-
als exploring the role of DD-CT have reported negative 
results [6-8]. The most recent meta-analysis by the Early
Breast Cancer Trialists' Collaborative Group found that DD-
CT lowers the risk of recurrence and breast cancer death by
approximately 15% in early breast cancer [5]. In Korea, long-
acting G-CSF is now available, but DD-CT is not commonly
used as is the case in Western settings. The reasons for this
are a lack of safety data for DD-CT in Korean patients and
non-reimbursement of long-acting G-CSF for DD-CT. 
DD-CT may increase most chemotherapy-related toxici-
ties. In individual trials, non-hematologic and hematologic
AEs, except neutropenia, were higher for DD-CT than for
Table 2.  Adverse events
Adverse event All grades Grade 1-2 Grade 3-4(n=63) (n=63) (n=63)
Hematologic
Neutropenia 12 (19) 10 (16) 2 (3)
Anemia 56 (89) 54 (86) 2 (3)
Thrombocytopenia 8 (13) 8 (13) 0 (
Lymphopenia 50 (79) 41 (65) 9 (14)
Febrile neutropenia 1 (2) - 1 (2)
Non-hematologic
Infection 10 (16) 8 (13) 2 (3)
Alopecia 27 (43) 27 (43) 0 (
Asthenia 25 (40) 25 (40) 0 (
Anorexia 15 (24) 15 (24) 0 (
Nausea 37 (59) 37 (59) 0 (
Vomiting 2 (3) 2 (3) 0 (
Stomatitis 24 (38) 23 (37) 1 (2)
Diarrhea 10 (16) 10 (16) 0 (
Constipation 11 (17) 11 (17) 0 (
Bone pain 8 (13) 8 (13) 0 (
Myalgia 22 (35) 22 (35) 0 (
Pain, others 34 (54) 34 (54) 0 (
Cough 17 (27) 17 (27) 0 (
Dizziness 21 (33) 21 (33) 0 (
Dyspepsia 25 (40) 25 (40) 0 (
Insomnia 15 (24) 15 (24) 0 (
Transaminase elevation 28 (44) 28 (44) 0 (
Others 38 (60) 38 (60) 0 (
Values are presented as number (%).
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conventional schedule chemotherapy [2,6-9]. Petrelli et al.
[19] reported that grade 3 to 4 neutropenia and FN rates were
not different between DD-CT and conventional chemother-
apy, but rates of anemia and thrombocytopenia were signif-
icantly higher (relative risk [RR], 3.48; 95% CI, 2.89 to 4.2, 
p < 0.001 and RR, 2.85; 95% CI, 1.93 to 4.2, p < 0.001) during
DD-CT than during conventional chemotherapy [19]. In this
study, the incidence of grade 3 or 4 AEs, including FN (1.6%),
was within an acceptable range and there were no toxicity-
related deaths. At least in terms of frequency of FN, DD-AC
with G-CSF support was safer than conventional AC
chemotherapy without G-CSF use.
Pegteograstim is a novel monoPEGylated recombinant
human G-CSF. It displays higher biological activity based on
an improved binding affinity to the G-CSF receptor [16-18].
Lee et al. [18] showed that pegteograstim was as effective as
pegfilgrastim in the reduction of chemotherapy-induced
neutropenia in breast cancer patients; the incidence of ADRs
was 5.3%, and most common ADRs were leukocytosis, blu-
rred vision, injection site pain, headache, and dizziness
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Fig. 1.  Change in hematology profiles on day 1 of each cycle (cycle 1 to 4) and end of treatment (4 weeks after the last chemo-
therapy). (A) Absolute lymphocyte count (ALC). (B) Hemoglobin level. (C) Platelet count. (D) Absolute neutrophil count
(ANC).
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[16,17]. In this study, the rate of ADRs for pegteograstim was
7.9% with AE profiles similar to the previous study.
We investigated the change in neutrophil, lymphocyte,
platelet, and hemoglobin level at every visit during DD-AC
chemotherapy (Fig. 1). Interestingly, lymphocyte count and
hemoglobin levels were not recovered one month after the
completion of chemotherapy. Although there was no case of
PJP in this study, the DD-AC regimen was one of the risk fac-
tors for PJP in the retrospective study by Waks et al. [10]
They suggested that a high-dose steroid used as an anti-
emetic over 8 weeks may increase the PJP risk in DD-AC. In
this study, we found that most patients had lymphopenia
after completion of DD-AC. Prolonged lymphopenia can
contribute to infectious vulnerability for PJP.
This study has several limitations. First, this was a small-
sized single-center study. Second, this study did not collect
patient-reported outcome (PRO) data. PRO data are increas-
ingly being implemented in oncology clinical trials to evalu-
ate disease-related symptoms, treatment-related AEs, and
health-related impacts on quality of life. We collected AE 
information from patients at regular visits and therefore AE
information may not be collected thoroughly. Third, 28.6%
of patients received DD-AC as neoadjuvant therapy in this
study. There is a possibility of different toxicity profiles bet-
ween neoadjuvant therapy and adjuvant therapy, despite the
regimens being identical.
In conclusion, DD-AC chemotherapy with pegteograstim
support is an efficacious and safe regimen in Korean patients
with early breast cancer. Reimbursement by the Korean gov-
ernment of long-acting G-CSF used for DD-CT is warranted
in early breast cancer patients.
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